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Abstract
Background: The classic model of estrogen action requires that the estrogen receptor (ER)
activates gene expression by binding directly or indirectly to DNA. Recent studies, however,
strongly suggest that ER can act through nongenomic signal transduction pathways and may be
mediated by a membrane bound form of the ER. Estradiol covalently linked to membrane
impermeable BSA (E2-BSA) has been widely used as an agent to study these novel membrane-
associated ER events. However, a recent report suggests that E2-BSA does not compete for E2
binding to purified ER in vitro. To resolve this apparent discrepancy, we performed competition
studies examining the binding of E2 and E2-BSA to both purified ER preparations and ER within
intact cells. To eliminate potential artifacts due to contamination of commercially available E2-BSA
preparations with unconjugated E2 (usually between 3–5%), the latter was carefully removed by
ultrafiltration.
Results: As previously reported, a 10-to 1000-fold molar excess of E2-BSA was unable to compete
with 3H-E2 binding to ER when added simultaneously. However, when ER was pre-incubated with
the same concentrations of E2-BSA, the binding of 3H-E2 was significantly reduced. E2-BSA binding
to a putative membrane-associated ER was directly visualized using fluorescein labeled E2-BSA (E2-
BSA-FITC). Staining was restricted to the cell membrane when E2-BSA-FITC was incubated with
stable transfectants of the murine ERα within ER-negative HeLa cells and with MC7 cells that
endogenously produce ERα. This staining appeared highly specific since it was competed by pre-
incubation with E2 in a dose dependent manner and with the competitor ICI-182,780.
Conclusions: These results demonstrate that E2-BSA does bind to purified ER in vitro and to ER
in intact cells. It seems likely that the size and structure of E2-BSA requires more energy for it to
bind to the ER and consequently binds more slowly than E2. More importantly, these findings
demonstrate that in intact cells that express ER, E2-BSA binding is localized to the cell membrane,
strongly suggesting a membrane bound form of the ER.
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Background
For many years, estrogen actions have been presumed to
be mediated almost exclusively through the regulation of
target gene transcription by a chromosomal bound estro-
gen receptor. These genomic estrogen effects are the well
described interactions between the estrogen receptor and
adapter transcription factors that result in activation or
inhibition of the basal transcription protein machinery.
However, there is a growing body of evidence that several
rapid estrogen effects are non-transcriptional in nature.
These rapid estrogen effects include changes of calcium
flux in several cell types [1-3], MAPK activation [4,5],
cAMP levels [6,7], and nitric oxide release [8]. That many
of these effects are mediated by a membrane-localized
estrogen receptor has been postulated for some time
[9,10], but the majority of evidence supporting this
hypothesis is indirect, relying on the induction of these
non-genomic effects using estrogen covalently conjugated
to BSA by a 6 atom hydrocarbon tether (E2-BSA) [11,12].
However, the relative binding efficiency of these conju-
gates is low and concern has been raised regarding the use
of these conjugates as direct surrogates for estrogen [13].
A recent report added to this controversy by showing that
commercially available E2-BSA is contaminated by uncon-
jugated free E2 and a series of binding experiments dem-
onstrated that E2-BSA was unable to bind to ER after the
contaminant E2 was removed. [14]. These findings contra-
dict studies where fluorescein-labeled E2-BSA (E2-BSA-
FITC) specifically bound to a putative ER on the cell mem-
brane [15-17].
Elucidation of novel membrane-associated ER effects is
crucial to our understanding of the non-genomic signal-
ing pathways of ER and other hormone receptors. Hor-
mone-conjugated BSA is an important tool in this pursuit.
We believe the contradictory results are explained by dif-
ferences in the rates of binding of the bulky E2-BSA and E2
with the ER. We show that pre-incubation of E2-BSA with
ERα results in a highly significant decrease in the binding
of 3H-E2. The binding of 3H-E2 with ERα is unaffected by
the simultaneous addition of E2-BSA. We also demon-
strate that fluorescein conjugated E2-BSA binds to the
membrane of cells that endogenously produce ERα and to
HeLa cell lines stably expressing mERα.
Results
E2-BSA binding to purified estrogen receptor
Although E2 is covalently attached to BSA using a rela-
tively long six atom hydrocarbon tether, the bulky BSA
moiety of E2-BSA still may be interfering with the binding
between the estrogen molecule and the estrogen receptor.
This would result in an increase in the energy of activation
required for E2-BSA binding. If so, increasing the reaction
time would allow for the establishment of an equilibrium
between bound and free forms of E2-BSA, maximizing the
amount of E2-BSA bound to the receptor. To test this
hypothesis, E2-BSA free of contaminant E2 was prepared
by ultrafiltration. Competition between the purified E2-
BSA and labeled E2 for binding to purified ERα was deter-
mined after E2-BSA was pre-incubated with ERα and also
when added at the same time as labeled E2. As shown in
figure 1, concurrent addition of labeled E2 and E2-BSA had
no effect on labeled E2 binding. However, a four-hour pre-
incubation of E2-BSA with ER significantly decreased E2
binding. These results suggest that the large BSA molecule
retards, but does not prevent binding of E2-BSA.
E2-BSA binding to ER in intact cells
Non-genomic actions of the estrogen receptor are now
well established. Several investigators have demonstrated
that fluorescein labeled E2-BSA (E2-BSA-FITC) binds to
the cell membrane, suggesting that a form of the estrogen
receptor is present within the cell membrane and capable
of binding to extracellular E2. Specific binding of E2-BSA-
FITC to this membrane-localized form of the ER would
further establish that E2 conjugated to the BSA molecule is
capable of binding to the ER. To examine this possibility,
E2-BSA-FITC binding studies were performed with MC7
cells that contain endogenous ERα and with ER-deficient
HeLa cells stably transfected with the ERα (HeLa-ERα).
Expression of ERα within the HeLa cells was established
by demonstrating specific binding of labeled E2 to HeLa-
ERα, but not native HeLa cells (figure 2). Scatchard anal-
ysis of the binding of E2 to HeLa-ERα cells showed that
although weakly expressed, the Kd for the expressed ERα
was 7.04 nM, similar to published values (figure 3). HeLa-
ERα cells, but not native HeLa cells, exhibited fluorescent
staining of the cell membrane after incubation with E2-
BSA-FITC (figure 4). The heterogeneous staining pattern
reflected the low level of ERα expression. This fluores-
cence was not seen when HeLa-ERα cells were incubated
with BSA conjugated to fluorescein alone (data not
shown).
To establish the specificity of E2-BSA binding, MC7 cells
and HeLa-ERα cells were incubated with E2-BSA-FITC
after pre-incubation with various concentrations of E2 and
the anti-estrogen ICI-182,780. As shown in figure 5,
fluorescence was lost in both cell types in a dose depend-
ent manner with increasing concentrations of E2. Fluores-
cence was almost completely eliminated by pre-
incubation with the specific competitor ICI-182,780. BSA
conjugated to FITC alone did not bind. These results sug-
gest that estrogen covalently bound to BSA can bind to ER
in a biologically significant manner.
The possibility that E2-BSA-FITC could be degraded dur-
ing incubation with intact cells was examined using
HPLC. E2-BSA-FITC was incubated in empty wells or wells
containing MC7 cells under the same conditionsNuclear Receptor 2004, 2:5 http://www.nuclear-receptor.com/content/2/1/5
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employed for the binding studies described above. Media
was removed from the cells and HPLC performed with a
reverse phase column. Peaks were visualized using a scan-
ning fluorescence detector. Aqueous solutions of E2-BSA-
FITC produced a single peak with a retention time of 5.5
minutes using a methanol-water gradient from 80% to
50% over 30 minutes at 1 ml/minute. E2 and E2-BSA did
not fluoresce at the excitation and emission wavelengths
used (data not shown). Spectra obtained from media con-
taining E2-BSA-FITC alone and media containing E2-BSA-
FITC incubated with MC7 cells are shown in figure 6. The
average area under the curve for E2-BSA-FITC was the same
(p < 0.05) for solutions incubated in the presence (44,556
+/- 432) and absence (43,436 +/- 289) of MC7 cells (p,
0.05). These results demonstrate that E2-BSA-FITC is sta-
ble under the culture conditions employed for the bind-
ing experiments.
Discussion
The cellular effects elicited by estrogen [11,12,18-20,3]
testosterone [3,21,22] and progesterone [23-25] cova-
lently conjugated to membrane impermeable BSA have
been attributed to non-genomic actions mediated by
membrane associated hormone receptors. The use of
these reagents for this purpose remains controversial for
several reasons. A recent report demonstrated that E2-BSA
Pre-incubation of purified hERα with E2-BSA competes for estradiol binding Figure 1
Pre-incubation of purified hERα with E2-BSA competes for estradiol binding. Purified ERα was incubated with E2 
(solid line) or E2-BSA (dotted line) for four hours before (a) or concurrently with (b) the addition of labeled E2. Incubation was 
continued for another 2 h at room temperature, and at the end of this period, specific binding was determined by adsorption, 
removal, and counting of free labeled E2.
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Whole cell binding of estradiol to MC7 cells and HeLa cells  stably transfected with ERα Figure 2
Whole cell binding of estradiol to MC7 cells and 
HeLa cells stably transfected with ERα. 2 × 106 cells 
were incubated with 3H-17β-estradiol (10-8 M) in the absence 
(solid) and presence (white) of 100 fold excess of unlabeled 
estradiol for 15 minutes at room temperature, washed, and 
placed on ice for 30 minutes. Cells were then pelleted, lysed 
and counted. Results are expressed as the mean +/- the SEM 
of 3 experiments (* p < 0.01)
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does not bind to purified ER in competition assays with
labeled E2 [14]. The studies were performed when E2-BSA
or cold E2 were added concurrently with labeled E2. We
obtained similar results under these conditions. However,
pre-incubation of E2-BSA with purified ER results in sig-
nificant competition with labeled E2. These conflicting
results may be explained by differences in the rate of bind-
ing between E2 and E2-BSA. E2-BSA is a large, bulky mole-
cule similar in size to the ER and is probably spherical in
general structure as is the parent BSA molecule. The BSA
protein conformation immediately adjacent to the cova-
lently bound estrogen undoubtedly provides substantial
steric hindrance to the proper presentation of conjugated
E2 to the binding pocket of ER. The increased size of the
E2-BSA molecule would also reduce the rate of its diffu-
sion compared with the smaller E2. Correct orientation of
E2 in the ER binding pocket is also impeded by the
restraint on three-dimensional movement imposed by the
six atom spacer used to connect BSA and E2. Lastly, the use
of E2-BSA solutions that are formulated in terms of the
molarity of total bound-E2 probably overestimates the
amount of E2 available for binding. The rate of binding
between E2 and ER can be expressed using the second
order rate equation: rate = k [E2] [ER], where [E2] is the
concentration of estradiol, [ER] is the concentration of the
ER, and k the rate constant.
Commercially available E2-BSA is commonly composed
of approximately 10 molecules of E2 attached to every
BSA molecule. An E2-BSA solution equimolar in estradiol
to a solution of estradiol alone would contain one-tenth
the molarity of E2-BSA with respect to the concentration
of estradiol alone. However the rate of E2-BSA binding is
dependent upon the concentration of E2-BSA (rate = k [E2-
BSA] [ER]). Even if every collision between E2-BSA and ER
produced binding as successful as collisions between E2
alone and the ER, an E2-BSA solution equimolar in E2
would have approximately one-tenth the rate.
Taken together, these factors reduce the binding efficiency
of E2-BSA to ER compared with free E2. However, once
binding has occurred, the stability of the E2 molecule in
the ER binding pocket may be only modestly impaired.
This may explain how pre-incubation with E2-BSA results
in successful binding, whereas immediate addition of E2-
BSA does not have sufficient time to establish successfully
bound forms. A similar rationale may explain our results
and those of other investigators [15] that demonstrate
specific cell surface binding of E2-BSA-FITC only to cells
that express ERα. These studies typically employ at least a
30-minute incubation time with E2-BSA-FITC, which may
be sufficient to result in significant binding. These factors
strongly suggest that the rate of binding is an important
consideration in experiments assessing potential interac-
tions between E2-BSA and ER.
Although an estrogen receptor has not been directly iso-
lated and characterized from the cell membrane, evidence
other than E2-BSA activation of non-genomic effects has
recently been reported that strongly supports the existence
Estradiol binding to HeLa cells stably transfected with ERα Figure 3
Estradiol binding to HeLa cells stably transfected with ERα. Subconfluent HeLa-ERα cells were trypsinized and aliq-
uots (2 × 106 cells) incubated with several concentrations of 3H-17β-estradiol in the presence and absence of a 200-fold excess 
of cold 17β-estradiol for 30 min at 37°. Cells were then incubated on ice for 15 min, washed three times with 2 ml of ice cold 
0.2% BSA-saline and pelleted by centrifugation at 1,5000 rpm for 10 min at 4°C. Cells were lysed by the addition of 100 ul of 
lysis buffer, vortexed and counted. a) Representative binding results of 3 independent experiments with total binding (solid 
box), non-specific binding (open box), and specific binding (triangle). b) Scatchard analysis of binding results.
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of a membrane ER. Immunocytochemistry using antibod-
ies specific to several domains of the ERα stained only on
the membrane of GH3 cells [26]. Membrane specific
staining was prevented by treatment with antisense ERα
Membrane localization of ERα Figure 4
Membrane localization of ERα. HeLa cells stably transfected with ERα(a) and native HeLa cells (b) were incubated with flu-
orescein labeled membrane impermeable BSA conjugated to estradiol (E2-BSA-FITC) and visualized under phase contrast 
bright field and with UV light with an excitation filter for FITC.
A
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E2 competition with E2-BSA-FITC binding Figure 5
E2 competition with E2-BSA-FITC binding. MC7 cells (black bars) or HeLa-ERα (white bars) were incubated with vehicle, 
various concentrations of E2, or ICI 182,780 (10-8 M) for 30 minutes and then incubated an additional 30 minutes with E2-BSA-
FITC or BSA-FITC alone (grey bar). Cells were fixed, and visualized by confocal microscopy. Digitized images were inverted to 
black on white and pixel density for each cell was determined by averaging the density across the cell membrane at four 
orthogonal points. Each bar represents >20 cells counted +/- SEM. (* p < 0.05).
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mRNA or peptides that interfere with antibody binding.
E2 conjugated to peroxidase also bound only to the mem-
brane of pancreatic islet cells and this binding was com-
peted by E2 [27]. The membrane impermeable E2-BSA-
FITC was shown to stain only the membrane of ER defi-
cient CHO cells transiently transfected with ERα and ERβ
[15]. Moreover, ERα and ERβ interact directly with the
membrane associated Src complex to trigger prostate
cancer cell proliferation through the RAF-1/Erk-2 signal
transduction pathway [5]. Lastly, we demonstrate that E2-
BSA-FITC membrane staining is absent with ER deficient
HeLa cells and present only on the membrane of cells that
endogenously produce ER or HeLa cells that stably express
mERα. Taken together these data strongly suggest that
non-genomic effects of E2 are at least partially mediated by
a membrane associated ER. However, whether the recep-
Stability of E2-BSA-FITC Figure 6
Stability of E2-BSA-FITC. E2-BSA-FITC (10-8 M in estrogen) was placed in empty wells or wells containing MC7 cells and 
incubated for 30 minutes at 4°C. E2-BSA-FITC was detected by reverse phase HPLC using a methanol-water gradient from 
80% methanol to 50% methanol over 30 minutes at 1.0 ml/min. The assay was run in triplicate. Representative spectra are 
shown for E2-BSA-FITC alone (A) and E2-BSA-FITC incubated with MC7 cells (B).
A BNuclear Receptor 2004, 2:5 http://www.nuclear-receptor.com/content/2/1/5
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tor is the classical nuclear ER translocated to the mem-
brane or an ER unique to the membrane remains
unanswered.
Conclusions
The results presented here suggest that E2-BSA can bind to
the estrogen receptor but the rate of binding is impeded
due to steric and other considerations. Commercially
available forms of the reagent are contaminated with dis-
sociable E2  and should be purified prior to studies
designed to demonstrate effects mediated through a mem-
brane ER. Although we demonstrate that classical nuclear
ERs can be translocated to the membrane, the conclusive
identity of the endogenous membrane receptor awaits
purification and sequencing of the putative membrane ER
protein.
Materials and Methods
Establishment of ER stable transfectants
Full-length cDNA encoding the mouse ERα was cloned
into a vector containing the CMV promoter driving the
neomycin resistance gene (pcERα). HeLa cells maintained
in MEM containing 10% fetal bovine serum under 5%
CO2 were transfected with pcERα and successful
transfectants (HeLa-ERα) were selected by survival in
media containing the neomycin analog, G418 (400 ug/
ml).
Preparation of E2-BSA free of E2
400 ul of E2-BSA (10-5 M in estrogen dissolved in 50 mM
tris, pH 8.5, Sigma) was added to a centrifugal filter unit
with a MW cut-off of 3,000 (Millipore) and centrifuged at
14,000 × g until 50 ul of retentate remained. The retentate
was washed 3 times with 350 ul of buffer, recovered and
volume adjusted to 400 ul.
Binding of estradiol to purified estrogen receptor
3H-labeled E2 (NEN, specific activity 48 Ci/mmol, 10-8 M)
was incubated with recombinant ERα (.035 pM, Alexis
Corp) for four hours at room temperature in binding
buffer (10 mM tris, 10% glycerol, 2 mM DTT, and 1 mg/
ml BSA). The binding of labeled E2 to ERα was competed
by various concentrations of ultrafiltered E2-BSA or E2 (10-
9 to 3.5 × 10-6 M in E2) added four hours prior to or con-
currently with the addition of labeled E2. ERα was
precipitated by the addition of a hydroxyapatite slurry
(50% v/v in TE) and centrifugation at 10,000 × g. The
pellet was washed three times with wash buffer (40 mM
tris, 100 mM KCl, 1 mM EDTA, and 1 mM EGTA) and 3H-
E2 binding determined by liquid scintillation counting.
E2-BSA-FITC binding to cell membranes of ER producing 
cells
HeLa-ERα cells or mammary tumor cells (MC7, ATTC)
were plated on glass cover slips and incubated with 500 ul
of 10-8 M (in estrogen) E2-BSA conjugated to FITC (E2-
BSA-FITC, Sigma, 10 moles E2 and 3.5 moles FITC per
mole BSA) or BSA-FITC (Sigma, equimolar to E2-BSA-
FITC with respect to BSA) for 30 minutes at 4°C. Binding
of E2-BSA-FITC to MC7 cells was competed by a 30 minute
pre-incubation with E2, ICI-182,780, or E2-BSA (Sigma,
10-7  to 10-9  M). Cells were fixed and FITC staining
visualized by confocal microscopy. Images were digitized,
inverted to black on white, and pixel density for each cell
determined by averaging the density across the cell
membrane at four orthogonal points (Scion Image, Scion
Corp).
The stability of E2-BSA-FITC during the incubation with
MC7 cells was assessed by HPLC. E2-BSA-FITC (500 ul, 10-
8 M in estrogen) was added to empty wells and to wells
containing MC7 cells prepared as above for 30 minutes at
4°C. 10 ul of supernatant was resolved using a C-18
reverse phase column (Xterra C-18 RP, 5 um, 4.6 mm ×
250 mm, Waters). A multiple solvent deliver system (BIO
CM 4000, Milton Roy) provided a methanol-water
gradient from 80% methanol to 50% methanol over 30
minutes at a flow rate of one ml/minute. Peaks were
detected by a scanning fluorescence detector (model 747,
Waters) at an excitation wavelength of 495 nm and emis-
sion wavelength of 519 nm. Area under the curve was cal-
culated using standard algorithms (Millenium Software).
Assays were performed in triplicate.
Estradiol binding studies
Subconfluent HeLa-ERα or native HeLa cells were
trypsinized and aliquots (2 × 106 cells) incubated with
several concentrations of 3H 17β-estradiol in the presence
and absence of a 200-fold excess of cold 17β-estradiol for
30 min at 37°. Cells were then incubated on ice for 15
min, washed three times with 2 ml of ice cold 0.2% BSA-
saline and pelleted by centrifugation at 1,5000 rpm for 10
min at 4°C. Cells were lysed by the addition of 100 ul of
lysis buffer, vortexed and counted. Data was analyzed by
Scatchard analysis.
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